In a new study that could ultimately lead to many new medicines, scientists from the Florida campus of The Scripps Research Institute (TSRI) have adapted a chemical approach to turn diseased cells into unique manufacturing sites for molecules that can treat a form of muscular dystrophy.
“We’re using a cell as a reaction vessel and a disease-causing defect as a catalyst to synthesize a treatment in a diseased cell,” said TSRI Professor Matthew Disney. “Because the treatment is synthesized only in diseased cells, the compounds could provide highly specific therapeutics that only act when a disease is present. This means we can potentially treat a host of conditions in a very selective and precise manner in totally unprecedented ways.”
The promising research was published recently in the international chemistry journal Angewandte Chemie.
Targeting RNA Repeats
In general, small, low molecular weight compounds can pass the blood-brain barrier, while larger, higher weight compounds tend to be more potent. In the new study, however, small molecules became powerful inhibitors when they bound to targets in cells expressing an RNA defect, such as those found in myotonic dystrophy.
Myotonic dystrophy type 2, a relatively mild and uncommon form of the progressive muscle weakening disease, is caused by a type of RNA defect known as a “tetranucleotide repeat,” in which a series of four nucleotides is repeated more times than normal in an individual’s genetic code. In this case, a cytosine-cytosine-uracil-guanine (CCUG) repeat binds to the protein MBNL1, rendering it inactive and resulting in RNA splicing abnormalities that, in turn, results in the disease.
In the study, a pair of small molecule “modules” the scientists developed binds to adjacent parts of the defect in a living cell, bringing these groups close together. Under these conditions, the adjacent parts reach out to one another and, as Disney describes it, permanently hold hands. Once that connection is made, the small molecule binds tightly to the defect, potently reversing disease defects on a molecular level.
“When these compounds assemble in the cell, they are 1,000 times more potent than the small molecule itself and 100 times more potent than our most active lead compound,” said Research Associate Suzanne Rzuczek, the first author of the study. “This is the first time this has been validated in live cells.”
The Latest on: Specific therapeutics
via Google News
The Latest on: Specific therapeutics
- Marker Therapeutics Reports Interim Results of its MultiTAA T Cell Therapy in Patients with Pancreatic Adenocarcinoma at AACRon July 20, 2019 at 8:00 am
About Marker Therapeutics, Inc. Marker Therapeutics ... is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor ... […]
- Does Silence Therapeutics plc (LON:SLN) Have A Particularly Volatile Share Price?on July 19, 2019 at 7:31 am
In order to fully understand whether SLN is a good investment for you, we also need to consider important company-specific fundamentals such as Silence Therapeutics’s financial health and ... […]
- Sjogren ’s syndrome Therapeutics Depth Analysis and Forecast by top Manufacturers are Allergan, Novartis, Biogen, F. Hoffmann-La Rocheon July 19, 2019 at 3:54 am
Nevertheless, the disease may also feature various organ manifestations. Sjogren’s syndrome therapeutics involves the use of specific treatments for each set of clinical features of the disease. As ... […]
- Fulcrum Therapeutics Opens Below IPO Priceon July 18, 2019 at 8:46 am
Fulcrum Therapeutics, Inc. (NASDAQ ... Fulcrum focuses on developing therapies for genetically defined diseases in areas of high unmet needs, with a specific focus on rare diseases. The company uses ... […]
- Cancer Therapeutics Market: Huge Advancement with Deep Insight Related to Growth Trends at a CAGR of 7.7% by 2026on July 18, 2019 at 6:35 am
Download PDF Report Sample @ www.alliedmarketresearch.com/request-sample/480 Recent progress in biological therapies have widened the scale of therapeutic targets for treatment of cancer with the ... […]
- SILENCE THERAPEUTICS AND MALLINCKRODT ANNOUNCE COLLABORATION TO DEVELOP AND COMMERCIALIZE RNAi THERAPEUTICS FOR COMPLEMENT-MEDIATED DISEASESon July 18, 2019 at 3:45 am
"This collaboration combines Silence Therapeutics' knowledge and world-class research ... Silence's proprietary technology is a highly specific and modular platform designed to inhibit or 'silence' ... […]
- Orum Therapeutics Raises $30M in Series B Financingon July 17, 2019 at 3:29 pm
Led by Sung Joo Lee, Ph.D., Founder and CEO, and Peter Park, Ph.D., Chief Scientific Officer, Orum Therapeutics develops Oromab, a proprietary cell-specific, cell-penetrating antibody platform ... […]
- Before You Buy Akari Therapeutics, Plc (NASDAQ:AKTX), Consider Its Volatilityon July 17, 2019 at 12:26 pm
In order to fully understand whether AKTX is a good investment for you, we also need to consider important company-specific fundamentals such as Akari Therapeutics’s financial health and ... […]
- Five Prime Therapeutics: A Hidden Gem And A Derisked Speculationon July 16, 2019 at 11:34 pm
Five Prime Therapeutics has its lead candidate, Bemarituzumab, in phase 3 trial targeting a specific form of gastric cancer. Although there’s no phase 2 data, phase 1 has decent results. ... […]
- Orum Therapeutics Announces $30 Million Series B Financing to Advance Cell-Penetrating, Cell-Specific Antibody Technology for Novel Therapeuticson July 16, 2019 at 9:00 pm
Financing proceeds to fund further platform development and therapeutic discovery in cancer and rare diseases, and expansion of Orum's new Boston R&D labs Orum Therapeutics announced today an ... […]
via Bing News